A Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis

Clinical trial NCT03443024 · COMPLETED

Trial details

NCT number: NCT03443024
Sponsor: Eli Lilly and Company
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Atopic Dermatitis

Start date: 2018-01-30
Primary completion: 2019-02-07
Enrollment: 280

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.